Lunit

Lunit P/TBV

The Price to Tangible Book Value (P/TBV) of Lunit (328130.KQ) as of Oct 16, 2026 is 231.32. In the previous year, Price to Tangible Book Value (P/TBV) was 259.05 — a change of -10.70% (lower).

P/TBV

231.32

YoY

-10.70%

Last updated:

Price to Tangible Book Value (P/TBV) of Lunit is 2024 231.32 . Price to Tangible Book Value (P/TBV) of Lunit was 2023 259.05 . It decreases by -10.70% lower compared to the previous year.

The Lunit P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2019
-20.60 KRW
Jan 1, 2020
-9.28 KRW
Jan 1, 2021
763.69 KRW
Jan 1, 2022
191.09 KRW
Jan 1, 2023
259.05 KRW
Jan 1, 2024
231.32 KRW
The Lunit P/TBV history
YEARP/TBVYoY
231.32-10.70%
259.05+35.57%
191.09-74.98%
763.69-8,331.32%
-9.28-54.97%
-20.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lunit Stock analysis

What does Lunit do? Lunit Inc is a South Korean company headquartered in Seoul, operating within the Health Care sector. The company has 293 employees and went public on July 21, 2022, with its ticker listed as 328130.KQ and ISIN KR7328130000. Lunit provides software solutions for medical diagnostic imaging services, focusing on the development and supply of AI-powered medical software. Its offerings include cancer diagnostic aid solutions, cancer early detection solutions, and cancer risk prediction solutions. The company's technology leverages artificial intelligence to enhance diagnostic capabilities in healthcare settings. Lunit's website is www.lunit.io, where further information about its services and solutions can be accessed. The company operates in the Health Care industry, specifically targeting medical imaging and AI-driven diagnostic tools. As of the latest available data, Lunit is engaged in the development and commercialization of AI-based medical software, aiming to improve the accuracy and efficiency of cancer-related diagnostics. The firm's IPO date marks its transition to a publicly traded company, reflecting its growth and market position in the healthcare technology space. Lunit's focus on AI applications in medical imaging positions it as a key player in the digital health sector, particularly within the Korean market and beyond. The company's solutions are designed to support healthcare professionals in making more informed diagnostic decisions, potentially reducing the time and resources required for cancer detection and treatment planning. Lunit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lunit stock

Price to Tangible Book Value (P/TBV) of Lunit is 231.32 in 2024.

Price to Tangible Book Value (P/TBV) of Lunit changed from 259.05 to 231.32, representing a -10.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Lunit since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Lunit with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lunit

All Key Metrics — Lunit